Dosing of PD-1 and PD-L1 inhibitors: Cost saving initiatives for significantly decreasing associated expenditure.
In: Journal of Oncology Pharmacy Practice, Jg. 27 (2021), Heft 1, S. 199-204
Online
academicJournal
Zugriff:
The article discusses that the global immune-oncology drug development pipeline has grown rapidly in a survey conducted in August 2019 there were active drugs in various stages of development, with programmed cell death 1 (PD-1) and programmed death-ligand 1 (PD-L1) among the most common targets. It mentions that the Immune checkpoint inhibitors (ICIs) are monoclonal antibodies directed at cytotoxic T lymphocyte-associated protein 4 (CTLA-4), PD-1 or PD-L1.
Titel: |
Dosing of PD-1 and PD-L1 inhibitors: Cost saving initiatives for significantly decreasing associated expenditure.
|
---|---|
Autor/in / Beteiligte Person: | Gilbar, Peter J ; Davis, Mark R |
Link: | |
Zeitschrift: | Journal of Oncology Pharmacy Practice, Jg. 27 (2021), Heft 1, S. 199-204 |
Veröffentlichung: | 2021 |
Medientyp: | academicJournal |
ISSN: | 1078-1552 (print) |
DOI: | 10.1177/1078155220974077 |
Schlagwort: |
|
Sonstiges: |
|